natgillin/translations-raw huggingface dataset:
Increase in certain white blood cells (eosinophilia), low platelet count (thrombocytopenia), severe allergic reaction (anaphylactic reaction), allergic reaction (e.g. rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), low blood sugar levels (in diabetic patients), feeling anxious, somnolence, impaired vision, fast heart beat (tachycardia), dry mouth, upset stomach, taste disturbance (dysgeusia), abnormal liver function (Japanese patients are more likely to experience these side effects), eczema (a skin disorder), redness of skin, hives (urticaria), severe drug rash, joint pain (arthralgia), pain in extremity, tendon pain, flu-like-illness, decreased haemoglobin (a blood protein), increased levels of uric acid, increased hepatic enzymes or creatine phosphokinase in the blood. 
teška alergijska reakcija (anafilaktička reakcija), alergijska reakcija (npr. osip, svrbež, otežano disanje, piskanje, oticanje lica ili nizak krvni tlak), niske razine šećera u krvi (u bolesnika sa šećernom bolesti), osjećaj tjeskobe, izrazita pospanost, oštećen vid, ubrzani otkucaji srca (tahikardija), suha usta, nadražaj želuca, poremećaj osjeta okusa (disgeuzija), abnormalna funkcija jetre (vjerojatnost da će iskusiti ovu nuspojavu, veća je za bolesnike iz Japana), ekcem (poremećaj kože), crvenilo kože, koprivnjača
LIST OF EXCIPIENTS Contains sorbitol (E420). 
3. POPIS POMOĆNIH TVARI Sadrži sorbitol (E420).
White to off white, oval shaped tablet; one side of the tablet is debossed with the number "93". 
Bijele do gotovo bijele, ovalne tablete; na jednoj strani tablete s utisnut je broj "93".
Each tablet contains 85.6 mg sorbitol (E420) For the full list of excipients, see section 6.1. 
Svaka tableta sadrži 85,6 mg sorbitola (E420)
INFORMATION IN BRAILLE Telmisartan Teva 20 mg 
16. PODACI NA BRAILLEOVOM PISMU Telmisartan Teva 20 mg
INFORMATION IN BRAILLE Telmisartan Teva 80 mg 
16. PODACI NA BRAILLEOVOM PISMU Telmisartan Teva 80 mg
Respiratory, thoracic and mediastinal disorders Uncommon: 
Poremećaji dišnog sustava, prsišta i sredoprsja Manje često:
Povidone (PVP K-30) Sorbitol (E420) 
natrijev škroboglikolat (vrste A) poloksamer meglumin povidon (PVP K-30) sorbitol (E420) magnezijev stearat
Each Telmisartan Teva tablet contains 40 mg telmisartan. 
Svaka Telmisartan Teva tableta sadrži 40 mg telmisartana.
INFORMATION IN BRAILLE Telmisartan Teva 40 mg 
16. PODACI NA BRAILLEOVOM PISMU Telmisartan Teva 40 mg
Each Telmisartan Teva tablet contains 20 mg telmisartan. 
Svaka Telmisartan Teva tableta sadrži 20 mg telmisartana.
Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. 
Kao i s ostalim vazodilatatorima, potreban je poseban oprez u bolesnika koji imaju aortalnu ili mitralnu stenozu ili opstruktivnu hipertrofičnu kardiomiopatiju.
Therefore, in these patients an approptiate blood glucose monitoring should be considered; a dose adjustment of insulin or antidiabetics may be required, when indicated. 
Stoga, u ovih bolesnika treba adekvatno kontrolirati glukozu u krvi.
The most prominent manifestations of telmisartan overdose were hypotension and tachycardia; bradycardia dizziness, increase in serum creatinine, and acute renal failure have also been reported. 
Najizraženije manifestacije predoziranja telmisartanom bile su hipotenzija i tahikardija.
Meglumine 
Vrtoglavica
Before considering the concomitant use of medicinal products that affect the renin-angiotensin-aldosterone system, the benefit risk ratio should be evaluated. 
Prije razmatranja istodobne primjene lijekova koji utječu na sustav renin-angiotenzin-aldosteron,
In addition, there was a significantly higher incidence of hyperkalaemia, renal failure, hypotension and syncope in the combination arm. 
zatajenja bubrega, hipotenzije i sinkope.
Pack sizes of 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tablets for peelable perforated blisters. 
Veličine pakovanja od 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tableta za perforirane blistere djeljive na jedinične doze.
Immune system disorders Rare: 
Poremećaji probavnog sustava Manje često:
Medicinal products or therapeutic classes of medicinal products that may provoke hyperkalaemia are salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti-inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim. 
Lijekovi ili terapijske klase lijekova koji mogu izazvati hiperkalijemiju su nadomjesci soli koje sadrže kalij, diuretici koji štede kalij, ACE-inhibitori, antagonisti receptora angiotenzina II, nesteroidni protuupalni (antiinflamatorni) lijekovi (NSAIL, uključujući selektivne COX-2 inhibitore), heparin, imunosupresivi (ciklosporin ili takrolimus) i trimetoprim.
Each Telmisartan Teva tablet contains 80 mg telmisartan. 
Svaka Telmisartan Teva tableta sadrži 80 mg telmisartana.
Each tablet contains 21.4 mg sorbitol (E420) For the full list of excipients, see section 6.1. 
Svaka tableta sadrži 21,4 mg sorbitola (E420)
You can also report side effects directly via the national reporting system listed in Appendix V By reporting side effects you can help provide more information on the safety of this medicine. 
Nuspojave možete prijaviti izravno putem nacionalnog sustava za prijavu nuspojava navedenog u Dodatku V.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. 
ALTITUDE (eng. Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) je bilo ispitivanje osmišljeno za testiranje koristi dodavanja aliskirena standardnoj terapiji s
NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non-selective NSAIDs) may reduce the antihypertensive effect of angiotensin II receptor antagonists. 
NSAIL) mogu smanjiti antihipertenzivni učinak antagonista receptora angiotenzina II.
Renal impairment including acute renal failure 
Oštećenje funkcije bubrega uključujući akutno zatajenje bubrega
Each tablet contains 42.8 mg sorbitol (E420) For the full list of excipients, see section 6.1. 
Svaka tableta sadrži 42,8 mg sorbitola (E420)
The use of angiotensin II receptor antagonists is not recommended during the first trimester of pregnancy (see section 4.4). 
Primjena antagonista receptora angiotenzina II se ne preporučuje tijekom prvog tromjesečja trudnoće
The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassiumsparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal antiinflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim). 
Rizik od hiperkalijemije se povećava u slučaju kombinacije s drugim lijekovima koji također mogu izazvati hiperkalijemiju (nadomjesci soli koji sadrže kalij, diuretici koji štede kalij, ACE-inhibitori, antagonisti receptora angiotenzina II, nesteroidni protuupalni lijekovi (NSAIL, uključujući selektivne COX-2 inhibitore), heparin, imunosupresivi (ciklosporin ili takrolimus) i trimetoprim).
Medicinal products or therapeutic classes of medicinal products that may provoke hyperkalaemia are salt substitutes containing potassium, 
• Lijekovi koji mogu povisiti razine kalija u krvi kao što su nadomjesci soli koje sadrže kalij,
This is confirmed by trough to peak ratios consistently above 80 % seen after doses of 40 and 80 mg of telmisartan in placebo controlled clinical studies. 
Ovo je potvrđeno omjerima minimalnih do maksimalnih vrijednosti koje su konstantno bile iznad 80 % nakon doza od
or have salt deficiency due to diuretic therapy (‘water tablets'), low-salt diet, diarrhoea, or vomiting. 
- Niski krvni tlak (hipotenzija), veća je vjerojatnost ove pojave ako ste dehidrirani (prekomjerni gubitak vode u tijelu) ili imate manjak soli zbog terapije diureticima (tablete za mokrenje), prehrane s niskim unosom soli, proljeva ili povraćanja.
• Medicines that may increase blood potassium levels such as salt substitutes containing potassium, potassium-sparing diuretics (certain ‘water tablets'), ACE inhibitors, angiotensin II receptor antagonists, NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen), heparin, immunosuppressives (e.g. cyclosporin or tacrolimus), and the antibiotic trimethoprim. 
• diuretici koji štede kalij (određene tablete za mokrenje), ACE-inhibitori, antagonisti receptora angiotenzina II, NSAIL (nesteroidni protuupalni lijekovi, npr. aspirin ili ibuprofen), heparin, imunosupresivi (npr. ciklosporin ili takrolimus) te antibiotik trimetoprim.
Treatment 
PROMET
Lithium 
Litij
Telmisartan Teva 80 mg tablets are white to off white, oval shaped tablets; one side of the tablet is debossed with the number "93". 
Kako Telmisartan Teva izgleda i sadržaj pakovanja Telmisartan Teva 80 mg tablete su bijele do gotovo bijele, ovalne tablete; na jednoj strani tablete je utisnut broj "93".
The recommended dose of Telmisartan Teva is one tablet a day. 
Teva je jedna tableta dnevno.
Sepsis (often called "blood poisoning", is a severe infection with whole-body inflammatory response usually accompanied by high fevers, hot, flushed skin, elevated heart rate, rapid breathing, altered mental status, swelling, and low blood pressure), rapid swelling of the skin and mucosa (angioedema); these side effects are rare (may affect up to 1 in 1,000 people) but are extremely serious and patients should stop taking the medicine and see their doctor immediately. 
Neke nuspojave mogu biti ozbiljne i zahtjevaju hitnu liječničku skrb: Ako Vam se pojave bilo koji od sljedećih simptoma, trebate odmah posjetiti svog liječnika: Sepsa (često nazvana „trovanje krvi“ je teška infekcija s upalnim odgovorom cijelog organizma obično popraćena visokom temperaturom, toplom, crvenom kožom, ubrzanim otkucajima srca (tahikardija), ubrzanim disanjem, mentalnim promjenama, oticanjem i niskim krvnim tlakom), brzo oticanje kože i sluznice (angioedem).
Telmisartan Teva 20 mg tablets are white to off white, oval shaped tablets; one side of the tablet is debossed with the number "93". 
Kako Telmisartan Teva izgleda i sadržaj pakovanja Telmisartan Teva 20 mg tablete su bijele do gotovo bijele, ovalne tablete; na jednoj strani tablete je utisnut broj "93".
Telmisartan Teva 40 mg tablets are white to off white, oval shaped tablets; one side of the tablet is debossed with the number "93". 
Kako Telmisartan Teva izgleda i sadržaj pakovanja Telmisartan Teva 40 mg tablete su bijele do gotovo bijele, ovalne tablete; na jednoj strani tablete je utisnut broj "93".
NAME OF THE MEDICINAL PRODUCT Telmisartan Teva 40 mg tablets 
NAZIV GOTOVOG LIJEKA Telmisartan Teva 40 mg tablete
NAME OF THE MEDICINAL PRODUCT Telmisartan Teva 80 mg tablets telmisartan 
NAZIV GOTOVOG LIJEKA Telmisartan Teva 80 mg tablete telmisartan
For reduction of cardiovascular events, the usual dose of Micardis is one 80 mg tablet once a day. 
Kardiovaskularna prevencija Preporučena doza je 80 mg jedanput na dan.
NAME OF THE MEDICINAL PRODUCT Telmisartan Teva 40 mg tablets telmisartan 
NAZIV GOTOVOG LIJEKA Telmisartan Teva 40 mg tablete telmisartan
NAME OF THE MEDICINAL PRODUCT Telmisartan Teva 20 mg tablets telmisartan 
NAZIV GOTOVOG LIJEKA Telmisartan Teva 20 mg tablete telmisartan
NAME OF THE MEDICINAL PRODUCT Telmisartan Teva 80 mg tablets 
NAZIV GOTOVOG LIJEKA Telmisartan Teva 80 mg tablete
Teva Pharma Belgium N.V./S.A. 
Teva Pharma B.V.
NAME OF THE MEDICINAL PRODUCT Telmisartan Teva 20 mg tablets 
NAZIV GOTOVOG LIJEKA Telmisartan Teva 20 mg tablete
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 40 mg telmisartan Excipients with known effect: 
KVALITATIVNI I KVANTITATIVNI SASTAV Svaka tableta sadrži 40 mg telmisartana.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 80 mg telmisartan Excipients with known effect: 
KVALITATIVNI I KVANTITATIVNI SASTAV Svaka tableta sadrži 80 mg telmisartana.
EU/1/09/610/041 14x1 tablets EU/1/09/610/042 28x1 tablets EU/1/09/610/043 30x1 tablets EU/1/09/610/044 40x1 tablets EU/1/09/610/045 56x1 tablets EU/1/09/610/046 60x1 tablets EU/1/09/610/047 84x1 tablets EU/1/09/610/048 90x1 tablets EU/1/09/610/049 98x1 tablets EU/1/09/610/050 
EU/1/09/610/041 14x1 tableta EU/1/09/610/042 28x1 tableta EU/1/09/610/043 30x1 tableta EU/1/09/610/044 40x1 tableta EU/1/09/610/045 56x1 tableta EU/1/09/610/046 60x1 tableta EU/1/09/610/047 84x1 tableta EU/1/09/610/048 90x1 tableta EU/1/09/610/049 98x1 tableta EU/1/09/610/050
MARKETING AUTHORISATION NUMBER(S) EU/1/09/610/021 Cartons of 14x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE GOTOVOG LIJEKA U PROMET EU/1/09/610/021 Kutije s 14x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 20 mg telmisartan Excipients with known effect: 
KVALITATIVNI I KVANTITATIVNI SASTAV Svaka tableta sadrži 20 mg telmisartana.
MARKETING AUTHORISATION NUMBER(S) EU/1/09/610/011 Cartons of 14x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE GOTOVOG LIJEKA U PROMET EU/1/09/610/011 Kutije s 14x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
MARKETING AUTHORISATION NUMBER(S) EU/1/09/610/001 Cartons of 14x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE GOTOVOG LIJEKA U PROMET EU/1/09/610/001 Kutije s 14x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal antiinflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim. 
diuretici koji štede kalij (određene tablete za mokrenje), ACE-inhibitori, antagonisti receptora angiotenzina II, NSAIL (nesteroidni protuupalni lijekovi, npr. aspirin ili ibuprofen), heparin, imunosupresivi (npr. ciklosporin ili takrolimus) te antibiotik trimetoprim.
EU/1/09/610/051 14x1 tablets EU/1/09/610/052 28x1 tablets EU/1/09/610/053 30x1 tablets EU/1/09/610/054 40x1 tablets EU/1/09/610/055 56x1 tablets EU/1/09/610/056 60x1 tablets EU/1/09/610/057 84x1 tablets EU/1/09/610/058 90x1 tablets EU/1/09/610/059 98x1 tablets EU/1/09/610/060 
EU/1/09/610/051 14x1 tableta EU/1/09/610/052 28x1 tableta EU/1/09/610/053 30x1 tableta EU/1/09/610/054 40x1 tableta EU/1/09/610/055 56x1 tableta EU/1/09/610/056 60x1 tableta EU/1/09/610/057 84x1 tableta EU/1/09/610/058 90x1 tableta EU/1/09/610/059 98x1 tableta EU/1/09/610/060
EU/1/09/610/031 14x1 tablets EU/1/09/610/032 28x1 tablets EU/1/09/610/033 30x1 tablets EU/1/09/610/034 40x1 tablets EU/1/09/610/035 56x1 tablets EU/1/09/610/036 60x1 tablets EU/1/09/610/037 84x1 tablets EU/1/09/610/038 90x1 tablets EU/1/09/610/039 98x1 tablets EU/1/09/610/040 100x1 tablets 
EU/1/09/610/031 14x1 tableta EU/1/09/610/032 28x1 tableta EU/1/09/610/033 30x1 tableta EU/1/09/610/034 40x1 tableta EU/1/09/610/035 56x1 tableta EU/1/09/610/036 60x1 tableta EU/1/09/610/037 84x1 tableta EU/1/09/610/038 90x1 tableta EU/1/09/610/039 98x1 tableta EU/1/09/610/040 100x1 tableta
EU/1/09/610/021 14x1 tablets EU/1/09/610/022 28x1 tablets EU/1/09/610/023 30x1 tablets EU/1/09/610/024 40x1 tablets EU/1/09/610/025 56x1 tablets EU/1/09/610/026 60x1 tablets EU/1/09/610/027 84x1 tablets EU/1/09/610/028 90x1 tablets EU/1/09/610/029 98x1 tablets EU/1/09/610/030 100x1 tablets 
EU/1/09/610/021 14x1 tableta EU/1/09/610/022 28x1 tableta EU/1/09/610/023 30x1 tableta EU/1/09/610/024 40x1 tableta EU/1/09/610/025 56x1 tableta EU/1/09/610/026 60x1 tableta EU/1/09/610/027 84x1 tableta EU/1/09/610/028 90x1 tableta EU/1/09/610/029 98x1 tableta EU/1/09/610/030 100x1 tableta
EU/1/09/610/011 14x1 tablets EU/1/09/610/012 28x1 tablets EU/1/09/610/013 30x1 tablets EU/1/09/610/014 40x1 tablets EU/1/09/610/015 56x1 tablets EU/1/09/610/016 60x1 tablets EU/1/09/610/017 84x1 tablets EU/1/09/610/018 90x1 tablets EU/1/09/610/019 98x1 tablets EU/1/09/610/020 100x1 tablets 
EU/1/09/610/011 14x1 tableta EU/1/09/610/012 28x1 tableta EU/1/09/610/013 30x1 tableta EU/1/09/610/014 40x1 tableta EU/1/09/610/015 56x1 tableta EU/1/09/610/016 60x1 tableta EU/1/09/610/017 84x1 tableta EU/1/09/610/018 90x1 tableta EU/1/09/610/019 98x1 tableta EU/1/09/610/020 100x1 tableta
EU/1/09/610/001 14x1 tablets EU/1/09/610/002 28x1 tablets EU/1/09/610/003 30x1 tablets EU/1/09/610/004 40x1 tablets EU/1/09/610/005 56x1 tablets EU/1/09/610/006 60x1 tablets EU/1/09/610/007 84x1 tablets EU/1/09/610/008 90x1 tablets EU/1/09/610/009 98x1 tablets EU/1/09/610/010 100x1 tablets 
EU/1/09/610/001 14x1 tableta EU/1/09/610/002 28x1 tableta EU/1/09/610/003 30x1 tableta EU/1/09/610/004 40x1 tableta EU/1/09/610/005 56x1 tableta EU/1/09/610/006 60x1 tableta EU/1/09/610/007 84x1 tableta EU/1/09/610/008 90x1 tableta EU/1/09/610/009 98x1 tableta EU/1/09/610/010 100x1 tableta
When driving vehicles or operating machinery it should be taken into account that dizziness or drowsiness may occasionally occur when taking antihypertensive therapy, such as Telmisartan Teva. 
Prilikom upravljanja vozilima ili strojevima, povremeno može doći do pojave omaglice ili pospanosti,
EU/1/09/610/005 Cartons of 56x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/005 Kutije s 56x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
EU/1/09/610/018 Cartons of 90x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/058 Kutije s 90x1 tableta u aluminij-aluminij perforiranom blisteru djeljivom na jedinične doze
EU/1/09/610/004 Cartons of 40x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/004 Kutije s 40x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
EU/1/09/610/019 Cartons of 98x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/049 Kutije s 98x1 tableta u aluminij-aluminij perforiranom blisteru djeljivom na jedinične doze
EU/1/09/610/025 Cartons of 56x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/025 Kutije s 56x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
EU/1/09/610/015 Cartons of 56x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/055 Kutije s 56x1 tableta u aluminij-aluminij perforiranom blisteru djeljivom na jedinične doze
To be taken into account with concomitant use 
Stoga se kombinacija mora oprezno primjenjivati,
EU/1/09/610/014 Cartons of 40x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/041 Kutije s 14x1 tableta u aluminij-aluminij perforiranom blisteru djeljivom na jedinične doze
EU/1/09/610/009 Cartons of 98x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/009 Kutije s 98x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
EU/1/09/610/007 Cartons of 84x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/007 Kutije s 84x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
EU/1/09/610/003 Cartons of 30x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/003 Kutije s 30x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
EU/1/09/610/006 Cartons of 60x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/006 Kutije s 60x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
EU/1/09/610/026 Cartons of 60x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/026 Kutije s 60x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
EU/1/09/610/017 Cartons of 84x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/047 Kutije s 84x1 tableta u aluminij-aluminij perforiranom blisteru djeljivom na jedinične doze
EU/1/09/610/008 Cartons of 90x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/008 Kutije s 90x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
EU/1/09/610/013 Cartons of 30x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/053 Kutije s 30x1 tableta u aluminij-aluminij perforiranom blisteru djeljivom na jedinične doze
EU/1/09/610/029 Cartons of 98x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/029 Kutije s 98x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
EU/1/09/610/010 Cartons of 100x1 tablets in peelable perforated unit-dose aluminium aluminium blisters 
EU/1/09/610/050 Kutije s 100x1 tableta u aluminij-aluminij perforiranom blisteru djeljivom na jedinične doze
EU/1/09/610/023 Cartons of 30x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/023 Kutije s 30x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 20 mg telmisartan 
2. KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNIH TVARI Svaka tableta sadrži 20 mg telmisartana.
EU/1/09/610/016 Cartons of 60x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/056 Kutije s 60x1 tableta u aluminij-aluminij perforiranom blisteru djeljivom na jedinične doze
EU/1/09/610/028 Cartons of 90x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/028 Kutije s 90x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
Tel/Tél: +32 3 820 73 73 
Teva Pharma Belgium N.V./S.A. Tel/Tél: +32 3 820 73 73
EU/1/09/610/024 Cartons of 40x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/024 Kutije s 40x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
EU/1/09/610/002 Cartons of 28x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/002 Kutije s 28x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
EU/1/09/610/027 Cartons of 84x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/027 Kutije s 84x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze
EU/1/09/610/012 Cartons of 28x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/052 Kutije s 28x1 tableta u aluminij-aluminij perforiranom blisteru djeljivom na jedinične doze
EU/1/09/610/022 Cartons of 28x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters 
EU/1/09/610/032 Kutije s 28x1 tableta u aluminij-aluminij perforiranom blisteru djeljivom na jedinične doze
Eye disorders Rare: 
Srčani poremećaji Manje često:
Serious adverse drug reactions include anaphylactic reaction and angioedema which may occur rarely (≥1/10,000 to < 1/1000), and acute renal failure. 
Teške nuspojave obuhvaćaju anafilaktičku reakciju i angioedem koji se mogu rijetko pojaviti
EU/1/09/610/020 Cartons of 100x1 tablets in peelable perforated unit-dose aluminium aluminium blisters 
EU/1/09/610/020 Kutije s 100x1 tableta u aluminij-aluminij perforiranom blisteru s odvojivim slojem djeljivom na jedinične doze